NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
SBI Schedules Analyst Meet on May 8, 2026, Following Q4FY26 Results
State Bank of India (SBIN) has announced an interaction with analysts and institutional investors scheduled for May 8, 2026, at 5:15 PM. This meeting will take place immediately following the declaration of the bank's Q4FY26 financial results. The event will be conducted in a hybrid format, featuring an in-person meeting at State Bank Bhavan, Mumbai, alongside a live webcast. This is a critical event for investors to understand the bank's performance trajectory and management's outlook for the next fiscal year.
முக்கிய அம்சங்கள்
Analyst and Institutional Investor meet scheduled for May 8, 2026, at 5:15 PM IST.The meeting is timed to follow the declaration of Q4FY26 financial results.Hybrid attendance options provided via in-person meet in Mumbai and a live webcast link.Management presentation will be made available on stock exchanges and the bank's website post-results.Discussion will be limited to information already available in the public domain.
👀 கவனிக்க வேண்டியவை
Investors should monitor the Q4 results and the subsequent management commentary for insights into credit growth, NIM trends, and asset quality guidance. The webcast link provides a transparent way for retail investors to hear management's strategic priorities firsthand.
Bigbloc Construction Receives Regulatory Approval for Merger of Subsidiary Companies
Bigbloc Construction Limited has received the final order from the Regional Director (NWR) for the merger of its subsidiary, Starbigbloc Building Material Limited, into its wholly-owned subsidiary, Bigbloc Building Elements Private Limited. The merger is effective from the appointed date of April 1, 2025, following approval under Section 233 of the Companies Act, 2013. This internal restructuring is designed to streamline the company's corporate structure and consolidate its building material operations. The official order was pronounced on April 28, 2026, and received by the company on May 2, 2026.
முக்கிய அம்சங்கள்
Merger of Starbigbloc Building Material Ltd into Bigbloc Building Elements Pvt Ltd approved by Regional Director.The appointed date for the merger is retrospective, set as April 1, 2025.Restructuring conducted under the fast-track merger provisions of Section 233 of the Companies Act, 2013.Consolidation aims to achieve operational synergies and reduce administrative overheads across subsidiaries.
👀 கவனிக்க வேண்டியவை
Investors should view this as a positive move towards corporate simplification and operational efficiency. No immediate action is required as this is an internal consolidation of existing business units.
Rubicon Research Completes Acquisition of 85% Stake in Arinna Lifesciences
Rubicon Research Limited has successfully completed the secondary acquisition of an 85% stake in Arinna Lifesciences Limited as of April 30, 2026. This transaction follows the initial agreement announced on April 15, 2026, and was executed under the terms of a Share Purchase Agreement. Consequently, Arinna Lifesciences has now become a subsidiary of Rubicon Research. This strategic move is expected to expand Rubicon's footprint and product portfolio in the pharmaceutical and life sciences sector.
முக்கிய அம்சங்கள்
Completed the acquisition of an 85% majority stake in Arinna Lifesciences Limited.Arinna Lifesciences Limited has officially become a subsidiary of the company as of April 30, 2026.The acquisition was a secondary purchase following a Share Purchase Agreement dated April 15, 2026.
👀 கவனிக்க வேண்டியவை
Investors should view this as a significant expansion move and monitor the upcoming quarterly results for the financial impact and synergy benefits of this acquisition.
BIL Vyapar CoC Discusses Resolution Plan Extension and Valuation in 8th Meeting
BIL Vyapar Limited, currently under the Corporate Insolvency Resolution Process (CIRP), held its 8th Committee of Creditors (CoC) meeting on April 30, 2026. The CoC discussed a request from a prospective resolution applicant for an extension of time to submit a resolution plan. The meeting also addressed the appointment of a co-ordinating valuer and the approval of CIRP costs. Furthermore, the committee is seeking a new accountant to prepare accounts for audit as the previous auditor expressed inability to perform the task.
முக்கிய அம்சங்கள்
Prospective resolution applicant has requested an extension of time for the submission of the Resolution Plan.CoC noted the valuation methodology and approved the appointment of a Co-ordinating Valuer.Committee of Creditors officially took note of and approved the CIRP costs incurred.Search for a new accountant initiated to prepare accounts for audit purposes following the withdrawal of the previous auditor.
👀 கவனிக்க வேண்டியவை
Equity shareholders should exercise extreme caution as CIRP proceedings often lead to significant capital erosion or delisting. Monitor the outcome of the resolution plan submission and the valuation reports to understand potential recovery values.
Cantabil Retail Adds 5 New Stores in April 2026, Total Store Count Reaches 658
Cantabil Retail India Limited has announced the opening of 5 new showrooms across various locations in India during the month of April 2026. This expansion brings the company's total retail footprint to 658 stores nationwide. The consistent addition of new outlets indicates a focused strategy on increasing market penetration and brand visibility. Investors should view this as a positive indicator of the company's ongoing organic growth trajectory.
முக்கிய அம்சங்கள்
Opened 5 new showrooms/shops across India in April 2026Total retail network increased to 658 showrooms/shopsExpansion reported under Regulation 30 of SEBI (LODR) Regulations, 2015Demonstrates continued physical footprint growth in the retail segment
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's quarterly revenue growth to see if the store expansion is translating into higher top-line performance. Watch for management commentary on same-store sales growth (SSSG) in upcoming earnings calls.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
ESAB India Appoints Curtis Evan Jewell as Non-Executive Chairman for 5-Year Term
ESAB India Limited has announced the appointment of Mr. Curtis Evan Jewell as its Non-Executive Nominee Director and Non-Executive Chairman, effective May 1, 2026. He replaces Mr. Kevin Johnson following a nomination withdrawal by ESAB Holdings Limited. Mr. Jewell is a Senior Vice President at the global ESAB Corporation and brings extensive experience in corporate governance, M&A, and legal affairs from his tenure at Colfax Corporation and Hogan Lovells. His appointment is for a five-year term and includes chairing the Risk Management Committee.
முக்கிய அம்சங்கள்
Appointment of Curtis Evan Jewell as Non-Executive Chairman for a 5-year term starting May 1, 2026Withdrawal of nomination for Kevin Johnson (DIN 09147729) effective from the same dateMr. Jewell currently serves as Senior Vice President and Corporate Secretary at ESAB CorporationNew Chairman will lead the Risk Management Committee and join Audit, NRC, SRC, and CSR committeesMr. Jewell holds a law degree from UPenn and a business certificate from The Wharton School
👀 கவனிக்க வேண்டியவை
This is a routine leadership transition within the parent group's nominee structure; investors should maintain their current positions as the change is unlikely to disrupt operations.
ESAB India Chairman Kevin Johnson Resigns Effective May 1, 2026
ESAB India Limited has announced that Mr. Kevin Johnson will step down as Nominee Director and Chairman effective May 1, 2026. This follows the withdrawal of his nomination by ESAB Holdings Limited due to personal reasons cited by Mr. Johnson. As a result of this cessation, he will also vacate his positions on several key board committees, including his role as Chairman of the Risk Management Committee. The board meeting confirming these changes was held on April 30, 2026, lasting approximately 21 minutes.
முக்கிய அம்சங்கள்
Mr. Kevin Johnson (DIN 09147729) to cease directorship effective May 1, 2026ESAB Holdings Limited withdrew the nomination via letter dated April 22, 2026Cessation includes membership in Audit, NRC, Stakeholders' Relationship, and CSR committeesVacates the position of Chairman of the Risk Management CommitteeBoard meeting for the announcement concluded at 17:30 hours on April 30, 2026
👀 கவனிக்க வேண்டியவை
Investors should watch for the appointment of a new Chairman to ensure smooth leadership transition. This change appears to be a routine administrative withdrawal of a nominee and is unlikely to impact daily operations.
Panacea Biotec Reports Fire at Baddi Oncology Facility; Operations Disrupted for 5-7 Days
Panacea Biotec's subsidiary, Panacea Biotec Pharma Limited, reported a fire incident at its Oncology Quality Control Laboratory in Baddi on April 30, 2026. The fire, caused by a short circuit, was quickly controlled, but operations at the facility are expected to be disrupted for approximately 5 to 7 days. Management has confirmed there were no casualties and that the facility is adequately insured. Importantly, the company does not anticipate a material impact on its overall financial performance due to this temporary halt.
முக்கிய அம்சங்கள்
Fire incident occurred at the Baddi, Himachal Pradesh facility on April 30, 2026, due to a short circuit.Operations at the Oncology Facility are temporarily disrupted for an estimated period of 5 to 7 days.Zero human casualties or injuries were reported during the incident.Management states the disruption is not likely to have a material impact on the company's financials.The facility has adequate insurance coverage and the insurance company has been notified.
👀 கவனிக்க வேண்டியவை
Investors should monitor for a follow-up announcement confirming the resumption of operations within the 7-day window. As the financial impact is expected to be immaterial, no immediate change in investment strategy is required.
IDBI Bank FY26 Net Profit Surges 27% to ₹9,513 Cr; Total Business Crosses ₹6 Trillion
IDBI Bank reported a strong full-year performance for FY26, with net profit growing 27% YoY to ₹9,513 crore, supported by a 14% growth in total business which crossed the ₹6 trillion milestone. While Q4 FY26 net profit saw a slight 5% YoY dip to ₹1,943 crore, the bank maintained exceptional asset quality with a Net NPA of 0.15% and a Provision Coverage Ratio of 99.39%. Capital adequacy remains robust at 26.65%, providing significant headroom for future credit expansion. However, the CASA ratio witnessed a slight compression, falling to 44.59% from 46.55% a year ago.
முக்கிய அம்சங்கள்
Full-year FY26 Net Profit increased by 27% YoY to ₹9,513 crore, while total business grew 14% to ₹6,00,789 crore.Asset quality significantly improved with Gross NPA falling 66 bps to 2.32% and Net NPA held steady at a very low 0.15%.Net Interest Income (NII) for Q4 FY26 grew 17% YoY to ₹3,851 crore with NIM improving to 4.15%.Capital position is exceptionally strong with CRAR at 26.65% and Tier 1 capital at 25.56%.Net advances grew by 16% YoY to ₹2,53,626 crore, with a retail-to-corporate mix of 70:30.
👀 கவனிக்க வேண்டியவை
Investors should focus on the bank's superior asset quality and high capital buffers which provide a strong foundation for credit growth. The consistent PCR above 99% and low Net NPA make it one of the cleanest balance sheets in the Indian banking sector.
IDBI Bank Appoints Abhijit Chakravorty and Ketan Vikamsey as Independent Directors for 2-Year Terms
IDBI Bank has approved the appointment of two seasoned professionals, Shri Abhijit Chakravorty and Shri Ketan Vikamsey, as Additional Independent Directors for two-year terms. Shri Chakravorty brings over 30 years of experience from SBI, including a stint as MD & CEO of SBI Cards. Shri Vikamsey is a senior partner at a major accounting firm and currently serves on the board of SBI. These appointments, effective in May and June 2026 respectively, are expected to strengthen the bank's corporate governance and credit oversight.
முக்கிய அம்சங்கள்
Shri Abhijit Chakravorty appointed for a 2-year term starting May 19, 2026.Shri Ketan Vikamsey appointed for a 2-year term starting June 26, 2026.Chakravorty previously served as MD & CEO of SBI Cards & Payment Systems Ltd and has 3 decades of experience at SBI.Vikamsey is a Senior Partner at KKC & Associates LLP and currently an Independent Director at State Bank of India.Both appointments are subject to shareholder approval and comply with SEBI (LODR) Regulations.
👀 கவனிக்க வேண்டியவை
The addition of high-caliber independent directors with deep banking and audit expertise is a positive signal for corporate governance. Investors should view this as a strengthening of the board's oversight capabilities.
IDBI Bank FY26 Net Profit Rises 26.6% to ₹9,513 Cr; Asset Quality Improves Significantly
IDBI Bank reported a robust performance for the financial year ended March 31, 2026, with a standalone net profit of ₹9,513.30 crore, a 26.6% increase from ₹7,515.17 crore in FY25. The bank's asset quality showed marked improvement, with Gross NPAs falling to 6.02% and Net NPAs reaching a low of 0.38%. Total income for the year grew to ₹35,743.53 crore, driven by steady interest and other income. The bank maintains a very strong capital position with a Capital Adequacy Ratio (CRAR) of 25.05%.
முக்கிய அம்சங்கள்
Annual Net Profit grew by 26.6% YoY to ₹9,513.30 crore from ₹7,515.17 croreGross NPA ratio improved to 6.02% as of March 31, 2026, compared to 6.99% YoYNet NPA ratio decreased to 0.38% from 0.48% in the previous financial yearCapital Adequacy Ratio (CRAR) remains robust at 25.05% with Tier 1 at 23.51%Annualized Return on Assets (ROA) for FY26 stood at a healthy 2.96%
👀 கவனிக்க வேண்டியவை
The consistent improvement in asset quality and strong profitability metrics make IDBI Bank a stable hold for long-term investors. Monitor the ongoing privatization process as it remains the primary catalyst for significant stock re-rating.
Panacea Biotec has received a favorable ruling from the Income Tax Appellate Tribunal (ITAT) regarding Assessment Year 2020-21. The ITAT set aside a previous order that had raised a tax demand of ₹9.16 Crore. This demand was originally based on a ₹3.44 Crore disallowance of expenses under Section 14A of the Income Tax Act. The ruling effectively cancels the entire demand, providing a positive financial impact for the company by removing this liability.
முக்கிய அம்சங்கள்
ITAT set aside the CIT(A) order dated August 14, 2025, for Assessment Year 2020-21Cancellation of a tax demand amounting to ₹9.16 CroreDeletion of expense disallowance of ₹3.44 Crore previously added under Section 14AThe ruling follows a Rectified Assessment Order originally passed on October 10, 2023
👀 கவனிக்க வேண்டியவை
This is a positive development as it removes a contingent liability and improves the company's financial position. Investors should continue to monitor the company's core business performance alongside such legal resolutions.
Biocon Receives 5 Procedural Observations from US FDA for Bengaluru Biosimilars Site
The U.S. FDA concluded a Pre-License Inspection at Biocon's Bengaluru biosimilars facility on April 29, 2026. The inspection covered 10 distinct areas including 3 manufacturing units, 5 labs, and 2 warehouses, resulting in a Form 483 with five observations. Biocon has stated these observations are procedural and do not involve data integrity or quality oversight issues. The company is now preparing a Corrective and Preventive Action (CAPA) plan to address the findings within the required timeline.
முக்கிய அம்சங்கள்
Inspection conducted between April 20 and April 29, 2026, at Biocon Park, Bengaluru.US FDA issued Form 483 with 5 observations across 3 manufacturing units and 5 labs.Observations are procedural in nature with no data integrity or quality oversight concerns.Zero repeat observations were noted during the conclusion of the audit.Company to submit a comprehensive CAPA plan to address all observations expeditiously.
👀 கவனிக்க வேண்டியவை
Investors should monitor the final classification of the inspection by the US FDA; while procedural observations are common, successful resolution is required for future product approvals from this site.
Bikaji Foods Promoters Confirm Zero Pledged Shares for FY26; Hold 73.88% Stake
Bikaji Foods' promoters have submitted their annual declaration confirming that no shares were pledged or encumbered during the financial year ended March 31, 2026. The promoter group collectively holds 18,52,39,398 shares, representing a significant 73.878% stake in the company. Key individual holders include Shiv Ratan Agarwal (33.70%) and Shiv Ratan Agarwal HUF (24.41%). This disclosure provides transparency regarding the stability of the promoter holding and the absence of debt-related risks associated with share pledging.
முக்கிய அம்சங்கள்
Promoter group holds a total of 18,52,39,398 equity shares as of March 31, 2026.Total promoter stake stands at 73.878% of the company's equity.Zero shares were encumbered or pledged, directly or indirectly, during FY 2025-26.Major shareholders include Shiv Ratan Agarwal (33.698%) and Deepak Agarwal (14.300%).
👀 கவனிக்க வேண்டியவை
The absence of pledged shares is a positive indicator of promoter financial health. Long-term investors can remain confident in the stability of the current shareholding structure.
Gufic Biosciences Invests USD 50,000 in Australian Biotech Firm Selvax
Gufic Biosciences has increased its stake in Selvax Pty Ltd, an Australian biotechnology company, by investing USD 50,000. The company subscribed to 378,350 ordinary shares at AUD 20 cents per share, bringing its total holding to 1,685,350 shares. This strategic investment is aimed at diversifying into the oncology immunotherapy sector, focusing on treatments for large solid tumors in humans and animals. Selvax has shown steady revenue growth, with its total income rising to AUD 356,972 for the year ended June 30, 2025.
முக்கிய அம்சங்கள்
Investment of USD 50,000 for 378,350 ordinary shares at AUD 20 cents per share.Total post-acquisition shareholding in Selvax increased to 1,685,350 shares.Selvax's annual income grew from AUD 220,435 in 2023 to AUD 356,972 in 2025.Strategic focus on proprietary immunotherapy for solid tumors including lung, pancreatic, and breast cancer.
👀 கவனிக்க வேண்டியவை
Investors should monitor this as a long-term strategic play in the high-growth oncology segment; while the current investment is small, successful commercialization of Selvax's technology could provide significant upside.
SBI Life FY26 Results: GWP Crosses INR 1 Trillion; Adjusted PAT Grows 29% YoY
SBI Life delivered a robust performance for FY26, with Gross Written Premium (GWP) crossing the INR 1,012.9 billion mark, a 19% YoY growth. While reported PAT grew 2% to INR 24.7 billion, adjusted for one-time GST and labor law impacts, PAT growth was a strong 29% at INR 31.2 billion. The Value of New Business (VoNB) reached INR 66.7 billion with a healthy margin of 27.5%, supported by a 122% surge in individual pure protection APE. The company maintains a dominant 22.9% private market share in individual rated new business.
முக்கிய அம்சங்கள்
Gross Written Premium (GWP) surpassed INR 1,012.9 billion, registering a 19% YoY growth.Value of New Business (VoNB) grew 12% to INR 66.7 billion with a margin of 27.5% (29% excluding GST impact).Individual pure protection category saw exceptional growth of 122% on an APE basis.Indian Embedded Value (IEV) increased by 15% YoY to reach INR 807.9 billion.Assets Under Management (AUM) grew 9% to INR 4.9 trillion with a strong solvency ratio of 1.90.
👀 கவனிக்க வேண்டியவை
Investors should view the strong growth in high-margin protection and non-par segments as a positive indicator for long-term profitability. The company's ability to maintain industry-leading opex ratios and distribution efficiency through SBI's network makes it a preferred pick in the life insurance sector.
SEBI Issues Administrative Warning to Aditya Birla Money Over Cyber Security Framework
Aditya Birla Money Limited received an administrative warning from SEBI on April 27, 2026, following a thematic inspection conducted in February 2026. The regulator's observations specifically target lapses in cyber security, cyber resilience, and the company's technical glitch framework. While the company is currently implementing corrective measures, management has stated that there is no immediate impact on financials or operations. Investors should monitor the company's ability to resolve these technical compliance issues to avoid further regulatory scrutiny.
முக்கிய அம்சங்கள்
SEBI issued an administrative warning letter dated April 27, 2026, following a February 2026 inspection.Observations pertain to deficiencies in cyber security, cyber resilience, and technical glitch frameworks.The company confirmed the warning has no quantifiable impact on its financial or operational activities.Corrective actions have been initiated by the company to address SEBI's observations within specified timelines.
👀 கவனிக்க வேண்டியவை
Investors should maintain their positions but monitor for any future technical disruptions that could indicate unresolved infrastructure issues. The current warning is administrative and non-financial, but persistent lapses could lead to stricter penalties.
Aditya Birla Money Head of Broking & Retail Saurabh Shukla Resigns After 15 Years
Mr. Saurabh Shukla, the Head of Broking & Retail Business at Aditya Birla Money Limited, has tendered his resignation to pursue external opportunities. His departure is effective from April 30, 2026, marking the end of a 15-year tenure with the organization. As a member of the Senior Management Personnel (SMP), his exit from a core business vertical is a significant leadership change. The company has not yet announced a successor for this critical retail-facing role.
முக்கிய அம்சங்கள்
Mr. Saurabh Shukla resigns as Head - Broking & Retail Business effective April 30, 2026The outgoing executive had a long-standing association of 15 years with the Aditya Birla GroupThe resignation was disclosed under Regulation 30 of SEBI (LODR) Regulations, 2015The departure is to pursue career opportunities outside the organization
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's announcement regarding a successor to ensure leadership continuity in the retail brokerage segment. No immediate portfolio changes are recommended, but the transition's impact on retail growth should be watched.
SBI Card Q4 FY26 PAT Rises 14% to ₹609 Cr; Asset Quality Improves Significantly
SBI Cards reported a steady performance for Q4 FY26, with Profit After Tax (PAT) growing 14% YoY to ₹609 Cr and full-year PAT increasing 13% to ₹2,167 Cr. While new account additions slowed to 917K from 1,109K YoY, total spends surged by 31% YoY to ₹1,15,350 Cr, indicating higher usage intensity. Asset quality showed notable improvement, with Gross NPA dropping to 2.41% from 3.08% and Net NPA falling to 1.04%. The company also maintained a strong capital position with a CRAR of 25.5%.
முக்கிய அம்சங்கள்
Q4 FY26 PAT increased by 14% YoY to ₹609 Cr, while full-year FY26 PAT rose 13% to ₹2,167 Cr.Card spends grew significantly by 31% YoY to ₹1,15,350 Cr in Q4, with market share in spends rising to 18.1% from 15.7%.Asset quality improved with Gross NPA at 2.41% (vs 3.08% YoY) and Net NPA at 1.04% (vs 1.46% YoY).Total Revenue for Q4 grew 7% YoY to ₹5,187 Cr, supported by a 13% increase in fee-based income.Capital Adequacy Ratio remains robust at 25.5%, with Tier 1 capital at 20.0%.
👀 கவனிக்க வேண்டியவை
Investors should focus on the significant improvement in asset quality and the robust 31% growth in spends as signs of healthy credit demand. However, monitor the 22% rise in annual operating costs and the slight dip in market share for card-in-force (18.6% vs 19.0%).
MobiKwik Group Secures RBI Approval for NBFC License to Expand Credit Offerings
One MobiKwik Systems has received RBI approval for its NBFC license application, which will be operated through its wholly-owned subsidiary, MobiKwik Financial Services Private Limited. This strategic milestone allows the company to leverage its 186 million+ registered user base and 4.79 million+ merchants to offer direct credit products. The license is expected to significantly improve lending margins and accelerate the time-to-market for new financial products. This move transitions MobiKwik into a full-stack fintech platform, enhancing its ability to serve underserved geographies.
முக்கிய அம்சங்கள்
RBI approval for NBFC license granted to subsidiary MobiKwik Financial Services Private LimitedApproval received in under four months, highlighting regulatory credibility and fast-track processingAccess to a massive ecosystem of 186 million+ users and 4.79 million+ merchants for credit distributionExpected to improve lending margins and provide access to sustainable capital through co-lending modelsMobiKwik holds an 18% market share of the PPI wallet gross transaction value as of December 2025
👀 கவனிக்க வேண்டியவை
This is a significant positive development that shifts MobiKwik from a distributor to a primary lender, likely improving unit economics and long-term profitability. Investors should monitor the rollout of new credit products and the impact on the company's Net Interest Margins (NIMs) in upcoming quarters.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
